98%
921
2 minutes
20
Background And Objectives: The U.S. Preventive Services Task Force (USPSTF) does not currently recommend routine screening for kidney cancer, even though approximately 14 390 people are expected to die from this disease in the United States in 2024. Individualized risk-based kidney cancer screening offers the potential to effectively detect cancer at an early stage and avoid unnecessarily screening the rest of the population who are at low risk. This study proposes electronic health records (EHR) risk evaluation for kidney cancer by examining a comprehensive set of medical history including diagnoses, comorbidities, viruses, and rare diseases.
Methods: The relevant medical history for predicting kidney cancer occurrence was identified from the analysis of All of Us data in three steps. First, a Systematized Nomenclature of Medicine (SNOMED) code binary indicator variable in EHR was set for the presence of kidney cancer. Second, the relationship between this binary indicator of cancer and all prior health conditions was examined using the Strong Rule for Feature Elimination and Least Absolute Shrinkage and Selection Operator logistic regression methods of variable selection. Third, the accuracy of the model was reported using cross-validated McFadden's R2 and Area under the Receiver Operating Characteristic curve (AROC) values.
Results: The analysis identified 133 out of an initial set of 25 683 clinical diagnoses (represented by SNOMED codes) that were predictive of kidney cancer. The model achieved a cross-validated McFadden's R2 of 0.195 and an AROC of 0.799. Most of the identified codes are consistent with the known risk factors for kidney cancer.
Conclusions: It is possible to accurately predict the risk of kidney cancer from medical history using this method. Additional studies to establish high-dimensional predictive risk factors are needed to see if EHR personalized risk prediction can lead to cost-effective cancer screening and eventually better clinical outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/QMH.0000000000000526 | DOI Listing |
World J Urol
September 2025
Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France.
Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.
Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, China.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are increasingly linked to immune-related kidney injury (irKI). This study presents the first bibliometric analysis of irKI research (2000-2025), aiming to identify key trends, mechanistic insights, and pharmacological risk factors. We analyzed 2,179 publications to understand the evolution of irKI research, focusing on areas like T cell-mediated tubular injury, immune system-driven inflammation, and changes in metabolism.
View Article and Find Full Text PDFTop Magn Reson Imaging
October 2025
BIOSPACE LAB, Nesles-la-Vallée, France.
Aims: Cardiac tumors are aggressive and asymptomatic in early stages, causing late diagnosis and locoregional metastasis. Currently, the standard of care uses gadolinium-based contrast agents for MRI, and the associated hypersensitivity reactions are a significant concern, such as gadolinium deposition disease. In addition, the proximity of cardiac lesions closer to vital structures complicates surgical interventions.
View Article and Find Full Text PDFCancer Med
September 2025
Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Introduction: Patients with chronic kidney disease (CKD) face unique challenges in cancer treatment, including the need for chemotherapy dose adjustments and avoiding nephrotoxic agents, often leading to less aggressive treatment. However, little is known about the real-world administration of adjuvant chemotherapy for patients with CKD. In this study, we aimed to investigate the prevalence of adjuvant chemotherapy in patients with CKD and to explore factors influencing chemotherapy use.
View Article and Find Full Text PDFJCI Insight
September 2025
Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Department of Pediatrics.
Methylmalonic acidemia (MMA) is a severe metabolic disorder affecting multiple organs because of a distal block in branched-chain amino acid (BCAA) catabolism. Standard of care is limited to protein restriction and supportive care during metabolic decompensation. Severe cases require liver/kidney transplantation, and there is a clear need for better therapy.
View Article and Find Full Text PDF